Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily

ClinicalTrials.gov ID: NCT01814137

Public ClinicalTrials.gov record NCT01814137. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised Trial Comparing Efficacy and Safety After Intensification With Either Insulin Aspart Once Daily as add-on or Changing to Basal Bolus Treatment With Insulin Degludec and Insulin Aspart in Subjects With Type 2 Diabetes Previously Treated With Insulin Degludec/Insulin Aspart Twice Daily (BOOST®: INTENSIFY BID)

Study identification

NCT ID
NCT01814137
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
40 participants

Conditions and interventions

Interventions

  • insulin aspart Drug
  • insulin degludec Drug
  • insulin degludec/insulin aspart Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2013
Primary completion
Feb 28, 2014
Completion
Feb 28, 2014
Last update posted
Mar 20, 2017

2013 – 2014

United States locations

U.S. sites
26
U.S. states
15
U.S. cities
25
Facility City State ZIP Site status
Novo Nordisk Investigational Site Goodyear Arizona 85395
Novo Nordisk Investigational Site Phoenix Arizona 85020
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site Greenbrae California 94904
Novo Nordisk Investigational Site San Diego California 92111
Novo Nordisk Investigational Site Spring Valley California 91978
Novo Nordisk Investigational Site Bradenton Florida 34201
Novo Nordisk Investigational Site Kissimmee Florida 34741
Novo Nordisk Investigational Site Plantation Florida 33324
Novo Nordisk Investigational Site Avon Illinois 46123
Novo Nordisk Investigational Site Crystal Lake Illinois 60012
Novo Nordisk Investigational Site Indianapolis Indiana 46254
Novo Nordisk Investigational Site Slidell Louisiana 70461-4231
Novo Nordisk Investigational Site Waltham Massachusetts 02453
Novo Nordisk Investigational Site Buckley Michigan 49620
Novo Nordisk Investigational Site Nashua New Hampshire 03063
Novo Nordisk Investigational Site Lawrenceville New Jersey 08648
Novo Nordisk Investigational Site Toms River New Jersey 08755-8050
Novo Nordisk Investigational Site Albany New York 12206
Novo Nordisk Investigational Site Myrtle Beach South Carolina 29572
Novo Nordisk Investigational Site Dallas Texas 75230
Novo Nordisk Investigational Site Dallas Texas 75251
Novo Nordisk Investigational Site Fort Worth Texas 76132
Novo Nordisk Investigational Site Olympia Washington 98502
Novo Nordisk Investigational Site Tacoma Washington 98405
Novo Nordisk Investigational Site Kenosha Wisconsin 53142

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01814137, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 20, 2017 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01814137 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →